Background: Patients with peripheral artery disease (PAD) are at heightened risk of
cardiovascular complications. The sodium-glucose cotransporter 2 inhibitor dapagliflozin …

Aims Because an increased risk of amputation with canagliflozin was reported in the
CANVAS trials, there has been a concern about the safety of sodium–glucose cotransporter …

Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–
glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …

Background Whether sodium glucose co-transporter 2 inhibitors (SGLT2i) are associated
with a lower risk of cardiovascular as well as adverse lower limb events in patients with type …

Aims To investigate cardiovascular (CV) safety and event rates for dapagliflozin versus other
glucose‐lowering drugs (GLDs) in a real‐world type 2 diabetes population after applying the …

Background: Dapagliflozin improved heart failure and kidney outcomes in patients with type
2 diabetes (T2DM) with or at high risk for atherosclerotic cardiovascular disease in the …

Importance Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal
glucose excretion and reduce cardiovascular (CV) deaths and hospitalizations for heart …

BACKGROUND: Apparent treatment-resistant hypertension (aTRH) is prevalent and
associated with adverse outcomes in heart failure with mildly reduced or preserved ejection …

Background Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT-2) inhibitor that
reduces blood glucose in patients with type 2 diabetes mellitus (T2DM) by promoting …

Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …